Change language:
The world’s largest food company began construction last week and plans to complete structural work at Rosbach vor der Höhe, north of Frankfurt, in the spring of next year.
Rosbach vor der Höhe is home to Nestlé’s Vitaflo business, which produces the Mevalia and Comidamed brands. Vitaflo, which was founded in the British city of Liverpool in 1997 and expanded to Germany in 2007, is part of Nestlé’s Life Sciences division.
Nestle said the Mevalia and Comidamed brands were acquired through Vitaflo in 2021 and that the company employs more than 300 people and materials in more than 40 countries. More than €8 million ($8. 6 million) is being invested in the Rosbach vor der Höhe plant. expand and modernize production. “
Production volumes will increase and jobs will be created as a result of the expansion project. Just Food asked Nestlé for specific details.
Alexander von Maillot, CEO of Nestlé for Germany, said in a statement: “By investing in innovation and employing cutting-edge technology, Vitaflo offers pioneering nutritional treatments at a clinical, fitness and affordable price to improve the quality of life for those affected.
Your email will arrive shortly
“For us this is as much a part of painting as it is of our vintage food products. “
The company described the Mevalia and Comidamed brands as “specialty foods” and “diet foods” designed to “improve the lives of people with rare congenital disorders of protein metabolism,” such as phenylketonuria. The products are prescribed by a doctor, Nestle said.
In Germany, one in every 10,000 newborns suffers from phenylketonuria, which requires “a protein-modified diet throughout life”.
David Jobse, Managing Director of Vitaflo in Germany, said: “Today we face the next steps in our company’s history. The investment in the renovation of the factory allows us to continue producing in accordance with quality standards.
“We already export our products to many countries around the world. In the future we will be even more competitive if we can meet the growing demand. “
Sales generated through Nestlé’s Life Sciences department amounted to CHF 6. 5 billion ($7. 2 billion) in fiscal 2023, compared to CHF 93 billion for the entire company.
Real internal expansion (GIR), a key indicator of Nestlé’s performance, fell 3. 2% last year for the business unit, compared to a 0. 3% drop at the organizational level. Organic growth of 1. 6%, less than 7. 2% of total business.
Check out all the newsletters of the GlobalData Media network.